… therapy for chronic hepatitis C virus (HCV) has evolved … -oral direct-acting antivirals (DAAs)
therapy. There are three … of the current use of pangenotypic DAAs concerning efficacy, safety, …

… a pan-genotypic, once daily direct-acting antiviral (DAA) to treat patients with chronic hepatitis
C virus (… In conclusion, Maviret is effective and safe for the treatment of Taiwanese patients …

… development goal of hepatitis C treatment and the prominent representatives of pan-genotypic …
hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa …

… Since the development of direct-acting antivirals( DAAs) for hepatitis C … distribution of RASs
between previously untreated chronic hepatitis C patients and patients with treatment failure. …

… Genetic diversity and evolution of hepatitis C virus–15 years … with potent, pangenotypic activity
against hepatitis C virus[J/… polymerase inhibitor for the treatment of chronic hepatitis C[J]. J …

… Value of triage treatment strategies to distribute hepatitis C … development of resistance. PLoS
One, 2021, 16(5):e0251934. … veterans affairs patients with hepatitis C virus infection. Am J …

… 摘要: 丙型肝炎病毒(hepatitis C virus,HCV)感染是全球性的… of the virus is one of the most
important treatment goals for … towards the discovery and development of novel inhibitors with …

… regimens for chronic hepatitis C are constantly evolving. DAAs will … strategies with DAAs in
the treatment for chronic hepatitis C. … of TG-2349,a pan-genotypic HCV protease inhibitor,in …

… The emergence and development of direct-acting antiviral agents (DAAs) have brought
great changes to the treatment of chronic hepatitis C.Nowadays the countries in the world are …

… efficacy of antiviral therapy based on sorfosbuvir (SOF) combination in the treatment of patients
with hepatitis C-… Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with …